Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149276 | 0.95 | ACHE (0.43) | ACHELMNAMAPTNTSR1HTT | |
| SCHEMBL5152286 | 0.89 | ACHE (0.47) | ACHELMNAMAPTNTSR1HTT | |
| SCHEMBL5151087 | 0.84 | MALT1 (0.43) | ACHELMNAMAPTNTSR1HTT | |
| SCHEMBL5149179 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2HRH3GAAKCNH2 | |
| SCHEMBL5149284 | 0.79 | ADORA3 (0.43) | LMNAMAPTHTT | |
| SCHEMBL5147908 | 0.77 | GSK3B (0.41) | SMN1; SMN2HRH3 | |
| SCHEMBL5152582 | 0.76 | BRD4 (0.39) | HRH3 | |
| SCHEMBL5149196 | 0.76 | KAT2B (0.47) | ACHEMAPTKMT2AHRH3GAA | |
| SCHEMBL27659533 | 0.76 | BRD4 (0.40) | MAPTHTTHRH3KDM4E | |
| SCHEMBL5152508 | 0.75 | TLR9 (0.48) | ACHELMNAHTTKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| CN-1938296-A | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists | ASTELLAS PHARMA INC (JP) | 2007-03-28 | — | — | CN | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | ACHE 33/4885LMNA 2809/4885MAPT 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.